{"entity":{"id":"nct07581912","kind":"trial","name":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases","aka":[],"tldr":"A phase 2 trial of Fulzerasib in Colorectal cancer, run by Zhejiang University, now recruiting.","summary":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases is a phase 2 interventional study registered as NCT07581912 by Zhejiang University, with 40 participants planned, started 2026-04-30 and due to reach its primary completion in 2028-12. Interventions recorded: fulzerasib; cetuximab N01. Conditions recorded: Colorectal Cancer, KRAS G12C Mutant Advanced Solid Tumors, Fulzerasib, Cetuximab N01.\n\nLinked to the drug Fulzerasib because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07581912","url":"https://clinicaltrials.gov/study/NCT07581912"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["fulzerasib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07581912","phase":"2","setting":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases","sponsor":"Zhejiang University","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07581912/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/"}]}}